25 XP   0   0   10

Knight Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Knight Therapeutics Inc together

PenkeI guess you are interested in Knight Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Knight Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Knight Therapeutics Inc

I send you an email if I find something interesting about Knight Therapeutics Inc.

Quick analysis of Knight Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Knight Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
C$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
C$7.76
Expected worth in 1 year
C$8.05
How sure are you?
76.9%

+ What do you gain per year?

Total Gains per Share
C$0.30
Return On Investment
5.6%

For what price can you sell your share?

Current Price per Share
C$5.30
Expected price per share
C$5.07 - C$5.69
How sure are you?
50%

1. Valuation of Knight Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

C$5.30

Intrinsic Value Per Share

C$7.30 - C$8.97

Total Value Per Share

C$15.05 - C$16.72

2. Growth of Knight Therapeutics Inc (5 min.)




Is Knight Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$599.8m$617.7m-$16.4m-2.7%

How much money is Knight Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$1.4m-$4.2m$2.8m198.9%
Net Profit Margin-2.4%-9.6%--

How much money comes from the company's main activities?

3. Financial Health of Knight Therapeutics Inc (5 min.)




What can you expect buying and holding a share of Knight Therapeutics Inc? (5 min.)

Welcome investor! Knight Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Knight Therapeutics Inc.

What can you expect buying and holding a share of Knight Therapeutics Inc?

First you should know what it really means to hold a share of Knight Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Knight Therapeutics Inc is C$5.3. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Knight Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Knight Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is C$7.76. Based on the TTM, the Book Value Change Per Share is C$0.07 per quarter. Based on the YOY, the Book Value Change Per Share is C$0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is C$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Knight Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 C$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per Share
Usd Eps0.071.3%-0.01-0.2%-0.04-0.7%0.010.2%0.040.8%
Usd Book Value Change Per Share0.163.1%0.051.0%0.071.3%0.020.4%0.152.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.163.1%0.051.0%0.071.3%0.020.4%0.152.8%
Usd Price Per Share3.31-3.50-3.90-4.36-5.09-
Price to Earnings Ratio12.33-10.83-32.47-65.84-50.37-
Price-to-Total Gains Ratio20.09-13.86-17.67-50.45-65.30-
Price to Book Ratio0.58-0.64-0.73-0.84-1.26-
Price-to-Total Gains Ratio20.09-13.86-17.67-50.45-65.30-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.90239
Number of shares256
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.050.02
Usd Total Gains Per Share0.050.02
Gains per Quarter (256 shares)14.086.00
Gains per Year (256 shares)56.3124.00
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10564602414
2011310204838
3016915807262
4022521409686
502822700120110
603383260144134
703943820168158
804504380192182
905074940216206
1005635500240230

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%7.05.00.058.3%12.08.00.060.0%30.09.00.076.9%30.09.00.076.9%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%14.06.00.070.0%30.09.00.076.9%30.09.00.076.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.039.00.0%0.00.039.00.0%
Total Gains per Share3.01.00.075.0%9.03.00.075.0%14.06.00.070.0%30.09.00.076.9%30.09.00.076.9%

Fundamentals of Knight Therapeutics Inc

About Knight Therapeutics Inc

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Fundamental data was last updated by Penke on 2024-03-09 21:38:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Knight Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Knight Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Knight Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 11.8% means that $0.12 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Knight Therapeutics Inc:

  • The MRQ is 11.8%. The company is making a huge profit. +2
  • The TTM is -2.4%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ11.8%TTM-2.4%+14.2%
TTM-2.4%YOY-9.6%+7.2%
TTM-2.4%5Y37.9%-40.3%
5Y37.9%10Y3,485.0%-3,447.1%
1.1.2. Return on Assets

Shows how efficient Knight Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Knight Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.9% Return on Assets means that Knight Therapeutics Inc generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Knight Therapeutics Inc:

  • The MRQ is 0.9%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -0.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.9%TTM-0.2%+1.1%
TTM-0.2%YOY-0.6%+0.4%
TTM-0.2%5Y0.2%-0.4%
5Y0.2%10Y1.1%-0.9%
1.1.3. Return on Equity

Shows how efficient Knight Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Knight Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.2% Return on Equity means Knight Therapeutics Inc generated $0.01 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Knight Therapeutics Inc:

  • The MRQ is 1.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -0.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.2%TTM-0.2%+1.4%
TTM-0.2%YOY-0.7%+0.5%
TTM-0.2%5Y0.3%-0.5%
5Y0.3%10Y1.1%-0.9%

1.2. Operating Efficiency of Knight Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Knight Therapeutics Inc is operating .

  • Measures how much profit Knight Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Knight Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 1.1% means the company generated $0.01  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Knight Therapeutics Inc:

  • The MRQ is 1.1%. The company is operating less efficient.
  • The TTM is 0.8%. The company is operating inefficient. -1
Trends
Current periodCompared to+/- 
MRQ1.1%TTM0.8%+0.3%
TTM0.8%YOY-4.1%+5.0%
TTM0.8%5Y84.0%-83.1%
5Y84.0%10Y4,459.5%-4,375.6%
1.2.2. Operating Ratio

Measures how efficient Knight Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.50 means that the operating costs are $1.50 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Knight Therapeutics Inc:

  • The MRQ is 1.496. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.281. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.496TTM1.281+0.215
TTM1.281YOY1.091+0.190
TTM1.2815Y1.284-0.003
5Y1.28410Y12.509-11.225

1.3. Liquidity of Knight Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Knight Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.49 means the company has $3.49 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Knight Therapeutics Inc:

  • The MRQ is 3.487. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.106. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.487TTM3.106+0.382
TTM3.106YOY2.672+0.433
TTM3.1065Y8.255-5.150
5Y8.25510Y48.268-40.012
1.3.2. Quick Ratio

Measures if Knight Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Knight Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 3.19 means the company can pay off $3.19 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Knight Therapeutics Inc:

  • The MRQ is 3.194. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.186. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.194TTM3.186+0.008
TTM3.186YOY2.496+0.690
TTM3.1865Y11.802-8.616
5Y11.80210Y63.369-51.567

1.4. Solvency of Knight Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Knight Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Knight Therapeutics Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.19 means that Knight Therapeutics Inc assets are financed with 19.4% credit (debt) and the remaining percentage (100% - 19.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Knight Therapeutics Inc:

  • The MRQ is 0.194. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.208. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.194TTM0.208-0.014
TTM0.208YOY0.166+0.042
TTM0.2085Y0.164+0.044
5Y0.16410Y0.090+0.074
1.4.2. Debt to Equity Ratio

Measures if Knight Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Knight Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 24.1% means that company has $0.24 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Knight Therapeutics Inc:

  • The MRQ is 0.241. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.263. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.241TTM0.263-0.021
TTM0.263YOY0.199+0.064
TTM0.2635Y0.215+0.048
5Y0.21510Y0.116+0.099

2. Market Valuation of Knight Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Knight Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Knight Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 12.33 means the investor is paying $12.33 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Knight Therapeutics Inc:

  • The EOD is 14.517. Based on the earnings, the company is underpriced. +1
  • The MRQ is 12.325. Based on the earnings, the company is underpriced. +1
  • The TTM is 10.827. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD14.517MRQ12.325+2.191
MRQ12.325TTM10.827+1.498
TTM10.827YOY32.475-21.648
TTM10.8275Y65.842-55.015
5Y65.84210Y50.366+15.476
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Knight Therapeutics Inc:

  • The EOD is 9.354. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 7.942. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -45.226. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD9.354MRQ7.942+1.412
MRQ7.942TTM-45.226+53.168
TTM-45.226YOY22.268-67.493
TTM-45.2265Y18.474-63.700
5Y18.47410Y-3.549+22.023
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Knight Therapeutics Inc is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Knight Therapeutics Inc:

  • The EOD is 0.683. Based on the equity, the company is cheap. +2
  • The MRQ is 0.580. Based on the equity, the company is cheap. +2
  • The TTM is 0.639. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.683MRQ0.580+0.103
MRQ0.580TTM0.639-0.059
TTM0.639YOY0.732-0.093
TTM0.6395Y0.840-0.201
5Y0.84010Y1.263-0.423
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Knight Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2240.075+200%0.091+145%0.032+604%0.199+13%
Book Value Per Share--7.7557.454+4%7.232+7%7.076+10%6.402+21%
Current Ratio--3.4873.106+12%2.672+31%8.255-58%48.268-93%
Debt To Asset Ratio--0.1940.208-7%0.166+17%0.164+19%0.090+116%
Debt To Equity Ratio--0.2410.263-8%0.199+21%0.215+12%0.116+108%
Dividend Per Share----0%-0%-0%-0%
Eps--0.091-0.015+116%-0.049+154%0.018+414%0.059+54%
Free Cash Flow Per Share--0.1420.018+674%0.039+259%-0.073+151%-0.033+124%
Free Cash Flow To Equity Per Share--0.035-0.020+159%-0.070+302%-0.158+555%0.153-77%
Gross Profit Margin--1.0001.914-48%-1.757+276%0.599+67%0.711+41%
Intrinsic Value_10Y_max--8.968--------
Intrinsic Value_10Y_min--7.296--------
Intrinsic Value_1Y_max---0.213--------
Intrinsic Value_1Y_min---0.210--------
Intrinsic Value_3Y_max--0.206--------
Intrinsic Value_3Y_min--0.180--------
Intrinsic Value_5Y_max--1.648--------
Intrinsic Value_5Y_min--1.457--------
Market Cap553113300.000+15%472701645.000521992289.790-9%614056403.868-23%754337962.519-37%873573305.513-46%
Net Profit Margin--0.118-0.024+120%-0.096+181%0.379-69%34.850-100%
Operating Margin--0.0110.008+34%-0.041+460%0.840-99%44.595-100%
Operating Ratio--1.4961.281+17%1.091+37%1.284+17%12.509-88%
Pb Ratio0.683+15%0.5800.639-9%0.732-21%0.840-31%1.263-54%
Pe Ratio14.517+15%12.32510.827+14%32.475-62%65.842-81%50.366-76%
Price Per Share5.300+15%4.5004.755-5%5.293-15%5.918-24%6.919-35%
Price To Free Cash Flow Ratio9.354+15%7.942-45.226+669%22.268-64%18.474-57%-3.549+145%
Price To Total Gains Ratio23.665+15%20.09313.861+45%17.666+14%50.451-60%65.304-69%
Quick Ratio--3.1943.186+0%2.496+28%11.802-73%63.369-95%
Return On Assets--0.009-0.002+118%-0.006+161%0.002+309%0.011-14%
Return On Equity--0.012-0.002+119%-0.007+159%0.003+353%0.011+5%
Total Gains Per Share--0.2240.075+200%0.091+145%0.032+604%0.199+13%
Usd Book Value--599837839.500601297554.2500%617719253.150-3%652424900.910-8%593399502.900+1%
Usd Book Value Change Per Share--0.1650.055+200%0.067+145%0.023+604%0.146+13%
Usd Book Value Per Share--5.7105.489+4%5.325+7%5.210+10%4.714+21%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.067-0.011+116%-0.036+154%0.013+414%0.044+54%
Usd Free Cash Flow--10955407.7001335280.050+720%3383298.500+224%-6932853.540+163%-3198728.385+129%
Usd Free Cash Flow Per Share--0.1040.013+674%0.029+259%-0.053+151%-0.025+124%
Usd Free Cash Flow To Equity Per Share--0.026-0.015+159%-0.052+302%-0.116+555%0.113-77%
Usd Market Cap407257322.790+15%348050221.214384342922.972-9%452129730.168-23%555419041.803-37%643212024.849-46%
Usd Price Per Share3.902+15%3.3133.501-5%3.897-15%4.357-24%5.094-35%
Usd Profit--7059644.400-1416825.275+120%-4234645.375+160%1843658.385+283%5093055.746+39%
Usd Revenue--60008450.00061786062.275-3%49733567.575+21%38357953.465+56%20134960.862+198%
Usd Total Gains Per Share--0.1650.055+200%0.067+145%0.023+604%0.146+13%
 EOD+4 -4MRQTTM+25 -9YOY+27 -75Y+22 -1210Y+20 -14

3.2. Fundamental Score

Let's check the fundamental score of Knight Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1514.517
Price to Book Ratio (EOD)Between0-10.683
Net Profit Margin (MRQ)Greater than00.118
Operating Margin (MRQ)Greater than00.011
Quick Ratio (MRQ)Greater than13.194
Current Ratio (MRQ)Greater than13.487
Debt to Asset Ratio (MRQ)Less than10.194
Debt to Equity Ratio (MRQ)Less than10.241
Return on Equity (MRQ)Greater than0.150.012
Return on Assets (MRQ)Greater than0.050.009
Total8/10 (80.0%)

3.3. Technical Score

Let's check the technical score of Knight Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.916
Ma 20Greater thanMa 505.372
Ma 50Greater thanMa 1005.458
Ma 100Greater thanMa 2005.362
OpenGreater thanClose5.410
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CAD. All numbers in thousands.

Summary
Total Assets1,011,149
Total Liabilities196,484
Total Stockholder Equity814,665
 As reported
Total Liabilities 196,484
Total Stockholder Equity+ 814,665
Total Assets = 1,011,149

Assets

Total Assets1,011,149
Total Current Assets401,296
Long-term Assets609,853
Total Current Assets
Cash And Cash Equivalents 61,149
Short-term Investments 93,417
Net Receivables 103,337
Inventory 112,447
Other Current Assets 40,487
Total Current Assets  (as reported)401,296
Total Current Assets  (calculated)410,837
+/- 9,541
Long-term Assets
Property Plant Equipment 20,455
Goodwill 85,883
Long Term Investments 129,340
Intangible Assets 311,201
Long-term Assets  (as reported)609,853
Long-term Assets  (calculated)546,879
+/- 62,974

Liabilities & Shareholders' Equity

Total Current Liabilities115,077
Long-term Liabilities81,407
Total Stockholder Equity814,665
Total Current Liabilities
Short Long Term Debt 25,684
Accounts payable 82,782
Other Current Liabilities 4,771
Total Current Liabilities  (as reported)115,077
Total Current Liabilities  (calculated)113,237
+/- 1,840
Long-term Liabilities
Long term Debt Total 54,493
Other Liabilities 26,914
Long-term Liabilities  (as reported)81,407
Long-term Liabilities  (calculated)81,407
+/-0
Total Stockholder Equity
Common Stock560,500
Retained Earnings 173,735
Capital Surplus 25,624
Other Stockholders Equity 54,806
Total Stockholder Equity (as reported)814,665
Total Stockholder Equity (calculated)814,665
+/-0
Other
Capital Stock560,500
Cash And Equivalents16,269
Cash and Short Term Investments 170,835
Common Stock Shares Outstanding 105,045
Liabilities and Stockholders Equity 1,011,149
Net Invested Capital 890,029
Net Tangible Assets 417,581
Net Working Capital 286,219
Property Plant and Equipment Gross 20,455



Balance Sheet

Currency in CAD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-31
> Total Assets 
86,483
260,324
261,614
486,613
525,424
530,136
627,821
648,988
638,336
867,999
877,904
990,770
994,293
991,980
993,467
1,005,983
1,016,853
1,029,133
1,041,406
1,051,832
1,058,191
1,074,371
1,022,261
1,305,303
1,267,135
1,224,748
1,013,963
1,039,676
1,000,795
1,043,647
1,037,614
991,891
995,422
1,001,134
1,035,343
1,054,836
1,044,774
1,013,743
1,011,149
1,011,1491,013,7431,044,7741,054,8361,035,3431,001,134995,422991,8911,037,6141,043,6471,000,7951,039,6761,013,9631,224,7481,267,1351,305,3031,022,2611,074,3711,058,1911,051,8321,041,4061,029,1331,016,8531,005,983993,467991,980994,293990,770877,904867,999638,336648,988627,821530,136525,424486,613261,614260,32486,483
   > Total Current Assets 
75,545
235,353
227,990
428,573
458,326
447,536
459,084
499,480
461,976
680,670
689,027
799,752
818,865
810,833
767,271
799,073
803,451
770,450
759,924
717,531
652,155
626,813
599,518
698,224
737,556
721,182
540,619
554,640
552,517
332,422
345,486
307,319
332,900
322,173
344,634
395,619
403,210
385,367
401,296
401,296385,367403,210395,619344,634322,173332,900307,319345,486332,422552,517554,640540,619721,182737,556698,224599,518626,813652,155717,531759,924770,450803,451799,073767,271810,833818,865799,752689,027680,670461,976499,480459,084447,536458,326428,573227,990235,35375,545
       Cash And Cash Equivalents 
75,449
234,507
227,223
283,445
301,293
329,047
246,606
237,481
204,785
363,713
389,402
514,942
519,522
527,879
506,839
496,460
583,408
418,358
303,222
244,785
231,110
294,911
319,125
169,268
262,623
340,275
218,091
229,592
271,218
102,582
92,490
85,963
113,457
93,119
101,822
71,679
56,218
36,730
61,149
61,14936,73056,21871,679101,82293,119113,45785,96392,490102,582271,218229,592218,091340,275262,623169,268319,125294,911231,110244,785303,222418,358583,408496,460506,839527,879519,522514,942389,402363,713204,785237,481246,606329,047301,293283,445227,223234,50775,449
       Short-term Investments 
0
0
0
143,501
154,404
114,874
208,616
257,314
252,672
311,473
289,845
272,897
285,891
269,061
249,208
291,421
208,184
343,826
445,855
459,033
407,440
319,697
266,548
261,348
269,025
206,337
185,192
181,747
151,232
87,171
77,417
77,030
56,940
56,812
60,492
119,542
127,156
124,916
93,417
93,417124,916127,156119,54260,49256,81256,94077,03077,41787,171151,232181,747185,192206,337269,025261,348266,548319,697407,440459,033445,855343,826208,184291,421249,208269,061285,891272,897289,845311,473252,672257,314208,616114,874154,404143,501000
       Net Receivables 
76
832
714
975
1,374
2,086
2,274
2,802
3,180
4,651
8,995
10,498
11,590
11,527
8,618
8,887
10,114
6,706
9,342
11,535
12,549
11,172
13,053
111,732
104,046
78,918
70,142
82,043
70,583
82,282
69,000
55,000
81,343
92,016
93,592
110,205
119,075
126,957
103,337
103,337126,957119,075110,20593,59292,01681,34355,00069,00082,28270,58382,04370,14278,918104,046111,73213,05311,17212,54911,5359,3426,70610,1148,8878,61811,52711,59010,4988,9954,6513,1802,8022,2742,0861,37497571483276
       Other Current Assets 
19
14
52
50
0
0
0
423
0
0
0
625
1,173
1,527
1,953
1,081
751
594
272
1,042
220
199
320
85,006
29,737
23,816
5,411
4,753
4,440
4,603
5,256
4,515
4,508
3,826
3,786
1,704
1,773
7,900
40,487
40,4877,9001,7731,7043,7863,8264,5084,5155,2564,6034,4404,7535,41123,81629,73785,0063201992201,0422725947511,0811,9531,5271,17362500042300050521419
   > Long-term Assets 
10,938
24,971
33,624
58,041
67,098
82,600
168,737
149,508
176,360
187,329
188,877
191,018
175,428
181,147
226,196
206,910
213,402
258,683
281,482
334,301
406,036
447,558
422,743
607,079
529,579
503,566
473,344
485,036
448,278
711,225
692,128
684,572
662,522
678,961
690,709
659,217
641,564
626,949
609,853
609,853626,949641,564659,217690,709678,961662,522684,572692,128711,225448,278485,036473,344503,566529,579607,079422,743447,558406,036334,301281,482258,683213,402206,910226,196181,147175,428191,018188,877187,329176,360149,508168,73782,60067,09858,04133,62424,97110,938
       Property Plant Equipment 
35
57
55
48
40
33
25
18
10
0
0
32
37
68
60
633
675
710
680
794
1,808
1,710
1,679
29,048
29,120
27,769
26,630
26,162
26,099
27,314
28,003
29,936
31,280
32,431
35,574
22,633
22,265
20,079
20,455
20,45520,07922,26522,63335,57432,43131,28029,93628,00327,31426,09926,16226,63027,76929,12029,0481,6791,7101,8087946807106756336068373200101825334048555735
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
88,262
84,341
80,443
77,770
77,725
74,091
76,273
75,999
75,403
80,749
79,818
83,412
82,274
84,797
85,738
85,883
85,88385,73884,79782,27483,41279,81880,74975,40375,99976,27374,09177,72577,77080,44384,34188,26200000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
116,239
115,344
120,591
160,484
167,182
171,559
215,876
213,760
267,918
340,504
382,637
359,229
259,717
197,690
175,787
162,185
174,841
153,853
193,732
175,865
178,952
155,391
148,610
149,739
158,016
141,903
139,258
129,340
129,340139,258141,903158,016149,739148,610155,391178,952175,865193,732153,853174,841162,185175,787197,690259,717359,229382,637340,504267,918213,760215,876171,559167,182160,484120,591115,344116,23900000000000
       Intangible Assets 
0
884
0
0
3,039
3,277
3,316
0
0
5,956
6,276
14,153
13,787
13,482
12,713
12,576
15,906
15,506
17,161
17,475
19,313
19,979
18,948
173,372
164,439
164,950
156,641
156,547
146,227
363,359
359,432
350,299
343,480
365,115
370,888
338,780
331,518
318,638
311,201
311,201318,638331,518338,780370,888365,115343,480350,299359,432363,359146,227156,547156,641164,950164,439173,37218,94819,97919,31317,47517,16115,50615,90612,57612,71313,48213,78714,1536,2765,956003,3163,2773,039008840
       Long-term Assets Other 
10,000
10,000
10,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,340
23,340
41,582
41,582
41,582
52,689
49,856
49,605
48,995
47,329
45,871
46,179
48,534
47,934
48,486
49,143
49,788
48,204
47,572
0
0
0047,57248,20449,78849,14348,48647,93448,53446,17945,87147,32948,99549,60549,85652,68941,58241,58241,58223,34023,34000000000000000010,00010,00010,000
> Total Liabilities 
2,990
1,768
1,036
7,622
5,973
3,797
2,372
6,926
5,663
6,034
8,305
11,052
10,998
11,800
13,019
14,775
15,370
15,824
21,004
21,800
25,640
26,251
64,082
390,197
390,774
345,750
131,741
153,435
171,320
154,207
165,017
149,873
165,843
171,445
180,827
228,979
225,905
206,544
196,484
196,484206,544225,905228,979180,827171,445165,843149,873165,017154,207171,320153,435131,741345,750390,774390,19764,08226,25125,64021,80021,00415,82415,37014,77513,01911,80010,99811,0528,3056,0345,6636,9262,3723,7975,9737,6221,0361,7682,990
   > Total Current Liabilities 
2,990
1,502
1,036
7,622
5,973
3,797
2,372
6,740
5,663
6,034
7,826
9,758
9,735
10,600
11,991
14,260
14,199
14,697
17,743
17,185
20,200
19,912
58,270
350,804
356,470
311,996
99,031
114,060
135,945
117,773
132,553
105,302
121,317
126,034
139,532
141,321
135,452
121,995
115,077
115,077121,995135,452141,321139,532126,034121,317105,302132,553117,773135,945114,06099,031311,996356,470350,80458,27019,91220,20017,18517,74314,69714,19914,26011,99110,6009,7359,7587,8266,0345,6636,7402,3723,7975,9737,6221,0361,5022,990
       Short-term Debt 
0
0
0
143,501
154,404
114,874
208,616
257,314
252,672
311,473
289,845
272,897
285,891
269,061
249,208
291,421
208,184
343,826
445,855
459,033
275
277
298
52,345
55,953
45,582
42,656
53,645
39,722
36,990
37,800
28,276
32,817
26,353
27,441
20,252
22,425
0
0
0022,42520,25227,44126,35332,81728,27637,80036,99039,72253,64542,65645,58255,95352,345298277275459,033445,855343,826208,184291,421249,208269,061285,891272,897289,845311,473252,672257,314208,616114,874154,404143,501000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
275
0
0
50,557
54,207
44,074
41,567
51,770
38,192
35,149
36,328
26,662
31,140
24,335
25,148
17,674
20,293
21,097
25,684
25,68421,09720,29317,67425,14824,33531,14026,66236,32835,14938,19251,77041,56744,07454,20750,5570027500000000000000000000
       Accounts payable 
183
849
547
591
1,600
1,503
801
39
1,294
1,289
1,870
748
2,933
3,123
4,146
541
4,592
4,100
5,401
752
8,323
7,481
9,298
72,831
79,770
66,518
42,475
44,512
45,385
66,127
76,792
65,309
77,944
82,402
90,865
106,061
107,989
93,537
82,782
82,78293,537107,989106,06190,86582,40277,94465,30976,79266,12745,38544,51242,47566,51879,77072,8319,2987,4818,3237525,4014,1004,5925414,1463,1232,9337481,8701,2891,294398011,5031,600591547849183
       Other Current Liabilities 
2,806
653
209
1,499
0
0
0
2,377
0
0
0
2,996
532
610
587
5,838
1,394
1,418
1,393
5,545
425
516
36,087
206,899
206,708
185,562
2,072
2,344
36,448
4,937
6,572
11,717
10,556
17,279
21,226
15,008
5,038
5,419
4,771
4,7715,4195,03815,00821,22617,27910,55611,7176,5724,93736,4482,3442,072185,562206,708206,89936,0875164255,5451,3931,4181,3945,8385876105322,9960002,3770001,4992096532,806
   > Long-term Liabilities 
0
266
0
0
0
0
0
186
0
0
479
1,294
1,263
1,200
1,028
515
1,171
1,127
3,261
4,615
5,440
6,339
5,812
39,393
34,304
33,754
32,710
39,375
35,375
36,434
32,464
44,571
44,526
45,411
41,295
87,658
90,453
84,549
81,407
81,40784,54990,45387,65841,29545,41144,52644,57132,46436,43435,37539,37532,71033,75434,30439,3935,8126,3395,4404,6153,2611,1271,1715151,0281,2001,2631,29447900186000002660
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
794
731
703
9,834
8,693
5,706
5,191
2,543
2,174
2,894
2,718
12,682
13,971
11,861
11,622
57,448
60,212
56,161
54,493
54,49356,16160,21257,44811,62211,86113,97112,6822,7182,8942,1742,5435,1915,7068,6939,83470373179400000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
1,294
1,263
1,200
1,028
515
1,171
1,127
3,261
4,615
4,646
5,608
5,109
29,559
25,611
28,048
27,519
36,832
33,201
33,540
29,746
31,889
30,555
33,550
29,673
0
0
28,388
26,914
26,91428,3880029,67333,55030,55531,88929,74633,54033,20136,83227,51928,04825,61129,5595,1095,6084,6464,6153,2611,1271,1715151,0281,2001,2631,29400000000000
> Total Stockholder Equity
83,493
258,556
260,578
478,991
519,451
526,339
625,449
642,062
632,673
861,965
869,599
979,718
983,295
980,180
980,448
991,208
1,001,483
1,013,309
1,020,402
1,030,032
1,032,551
1,048,120
958,179
810,731
783,561
791,866
882,222
886,241
829,475
889,440
872,597
842,018
829,579
829,689
854,516
825,857
818,869
807,199
814,665
814,665807,199818,869825,857854,516829,689829,579842,018872,597889,440829,475886,241882,222791,866783,561810,731958,1791,048,1201,032,5511,030,0321,020,4021,013,3091,001,483991,208980,448980,180983,295979,718869,599861,965632,673642,062625,449526,339519,451478,991260,578258,55683,493
   Common Stock
11,909
255,780
256,312
341,065
354,515
358,097
438,960
439,148
439,176
662,702
664,561
760,447
761,003
761,063
761,127
761,490
761,546
761,595
761,788
761,844
761,913
761,982
698,115
723,832
698,249
699,067
695,066
694,351
641,461
668,425
652,681
628,854
619,675
611,967
607,765
599,055
587,173
571,928
560,500
560,500571,928587,173599,055607,765611,967619,675628,854652,681668,425641,461694,351695,066699,067698,249723,832698,115761,982761,913761,844761,788761,595761,546761,490761,127761,063761,003760,447664,561662,702439,176439,148438,960358,097354,515341,065256,312255,78011,909
   Retained Earnings 
-76
315
877
125,859
139,675
148,195
154,472
160,026
160,503
164,949
170,647
178,586
184,633
185,092
188,685
195,830
214,952
218,971
231,901
232,122
237,311
256,267
227,405
52,246
40,760
58,209
166,306
174,545
181,207
207,645
199,531
191,647
172,920
175,503
176,909
161,755
158,978
162,449
173,735
173,735162,449158,978161,755176,909175,503172,920191,647199,531207,645181,207174,545166,30658,20940,76052,246227,405256,267237,311232,122231,901218,971214,952195,830188,685185,092184,633178,586170,647164,949160,503160,026154,472148,195139,675125,859877315-76
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,783
15,481
15,965
16,463
16,933
16,882
18,203
18,731
19,242
21,082
21,470
21,776
22,161
22,936
23,196
23,664
24,447
25,275
25,624
25,62425,27524,44723,66423,19622,93622,16121,77621,47021,08219,24218,73118,20316,88216,93316,46315,96515,48114,78300000000000000000000
   Treasury Stock000000000000000000000000000000000000000
   Other Stockholders Equity 
71,660
750
1,502
2,100
3,119
4,278
6,320
6,933
8,006
7,873
9,262
10,254
10,905
11,923
12,685
12,981
13,526
14,168
14,648
15,111
15,568
16,266
16,750
17,248
17,718
17,667
18,320
18,848
19,359
21,199
21,587
21,893
22,278
23,053
23,313
23,781
24,564
47,547
54,806
54,80647,54724,56423,78123,31323,05322,27821,89321,58721,19919,35918,84818,32017,66717,71817,24816,75016,26615,56815,11114,64814,16813,52612,98112,68511,92310,90510,2549,2627,8738,0066,9336,3204,2783,1192,1001,50275071,660



Balance Sheet

Currency in CAD. All numbers in thousands.




Cash Flow

Currency in CAD. All numbers in thousands.




Income Statement

Currency in CAD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue335,657
Cost of Revenue-180,332
Gross Profit155,325155,325
 
Operating Income (+$)
Gross Profit155,325
Operating Expense-338,350
Operating Income-2,693-183,025
 
Operating Expense (+$)
Research Development17,431
Selling General Administrative89,506
Selling And Marketing Expenses-
Operating Expense338,350106,937
 
Net Interest Income (+$)
Interest Income13,757
Interest Expense-10,691
Other Finance Cost-0
Net Interest Income3,066
 
Pretax Income (+$)
Operating Income-2,693
Net Interest Income3,066
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-18,97116,651
EBIT - interestExpense = -10,691
-7,697
2,994
Interest Expense10,691
Earnings Before Interest and Taxes (EBIT)--8,280
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-18,971
Tax Provision--11,274
Net Income From Continuing Ops-7,697-7,697
Net Income-7,697
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-19,344-3,066
 

Technical Analysis of Knight Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Knight Therapeutics Inc. The general trend of Knight Therapeutics Inc is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Knight Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Knight Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 5.65 < 5.69 < 5.69.

The bearish price targets are: 5.22 > 5.21 > 5.07.

Tweet this
Knight Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Knight Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Knight Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Knight Therapeutics Inc. The current macd is -0.03488836.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Knight Therapeutics Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Knight Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Knight Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Knight Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartKnight Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Knight Therapeutics Inc. The current adx is 20.11.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Knight Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Knight Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Knight Therapeutics Inc. The current sar is 5.221088.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Knight Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Knight Therapeutics Inc. The current rsi is 44.92. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Knight Therapeutics Inc Daily Relative Strength Index (RSI) ChartKnight Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Knight Therapeutics Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Knight Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Knight Therapeutics Inc Daily Stochastic Oscillator ChartKnight Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Knight Therapeutics Inc. The current cci is -22.47446084.

Knight Therapeutics Inc Daily Commodity Channel Index (CCI) ChartKnight Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Knight Therapeutics Inc. The current cmo is -11.50033144.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Knight Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartKnight Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Knight Therapeutics Inc. The current willr is -67.85714286.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Knight Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Knight Therapeutics Inc Daily Williams %R ChartKnight Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Knight Therapeutics Inc.

Knight Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Knight Therapeutics Inc. The current atr is 0.12759072.

Knight Therapeutics Inc Daily Average True Range (ATR) ChartKnight Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Knight Therapeutics Inc. The current obv is 1,780,929.

Knight Therapeutics Inc Daily On-Balance Volume (OBV) ChartKnight Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Knight Therapeutics Inc. The current mfi is 51.74.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Knight Therapeutics Inc Daily Money Flow Index (MFI) ChartKnight Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Knight Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-09STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-17STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Knight Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Knight Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.916
Ma 20Greater thanMa 505.372
Ma 50Greater thanMa 1005.458
Ma 100Greater thanMa 2005.362
OpenGreater thanClose5.410
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Knight Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Knight Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Knight Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Knight Therapeutics Inc

I send you an email if I find something interesting about Knight Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Knight Therapeutics Inc.

Receive notifications about Knight Therapeutics Inc in your mailbox!